Back to results
US 2014/0274951 A1Published application
Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
AssigneeAlbany Molecular Research, Inc.
InventorsPeter R. Guzzo, David D. Manning
Life of this patent
Estimating the term…
Abstract
The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.
Claims34
A conjugate compound of formula (I):
- wherein
- L is a cell-targeting ligand;
- T is a therapeutic agent, with the proviso that T is not CAS Registry No. 115834-23-6 (SF2446A1) or derivatives or analogues thereof;
- J is a linker group;
- X is independently selected from the group consisting of:
- (1) a bond;
- (2) O;
- (3)
- which is independently and optionally substituted from 1 to 2 times with R8, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
- and
- (4)
- which is independently and optionally substituted from 1 to 2 times with R8, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
- Q is —(CH2)n—, —CH2CHR1CH2—, —CH2CR5R6CH2—, —CH2CHR1CH2CH2—, —CH2CH2CHR1CH2CH2—, —CH2X1CH2—, or —CH2CH2X1CH2CH2—;
- R1 is C1-6 alkyl, aryl, heteroaryl, OR5, NR5R6, or —N(COR2)R7, each of which is optionally substituted with R8;
- R2 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with R8;
- R3 is H, C1-6 alkyl, C3-6 cycloalkyl, or —COR4, each of which is optionally substituted with R8;
- R4 is H, C1-6 alkyl, or C3-6 cycloalkyl, each of which is optionally substituted with R8;
- R5 is H or C1-6 alkyl optionally substituted with R8;
- R6 is H or C1-6 alkyl optionally substituted with R8;
- or
- R5 and R6 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
- R7 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with R8;
- R8 is H, NO2, CN, halogen, oxo, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, aryl, heteroaryl, COOR9, COR9, C(O)NR9R10, COONR9R10, SO2R9, SO2NR9R10, or OR9;
- R9 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
- R10 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
- or
- R9 and R10 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
- X1 is O, S, SO, SO2, or NR3;
- n is 1 to 5;
- and
- m is 1 to 8.
28 more elements
A conjugate compound of formula (III):
- wherein
- L is a cell-targeting ligand;
- T is a therapeutic agent, with the proviso that T is not CAS Registry No. 115834-23-6 (SF2446A1) or derivatives or analogues thereof;
- J is a linker group, with the proviso that when X is a bond, J cannot directly bond to the silicon atom with an O, NH, N—CH3, S, or carboxyl and forms a hydrolytically stable carbon bond with the silicon atom;
- X is independently selected from the group consisting of:
- (1) a bond;
- (2)
- which is independently and optionally substituted from 1 to 2 times with R′5, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
- and
- (3)
- which is independently and optionally substituted from 1 to 2 times with R′5, wherein the wavy lines indicate point of attachment sites and * is the point of attachment to J and ** is the point of attachment to Si;
- R13 and R14 are each independently selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl, aryl, and heteroaryl, each of which is optionally substituted with R16;
- R15 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, CN, halogen, NO2, oxo, aryl, heteroaryl, OR17, COOR17, COR17, CONR17R18, COONR17R18, SO2R17, or SO2NR17R18;
- R16 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyalkyl, C3-6 cycloalkyl, C4-7 cycloalkylalkyl, CN, halogen, NO2, OR17, NR17R18, COOR17, COR17, CONR17R18, SO2R17, —SO2NR17R18, aryl, or heteroaryl;
- R17 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
- R18 is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, aryl, or heteroaryl is optionally substituted from 1 to 3 times with halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;
- or
- R17 and R18 are taken together with the nitrogen to which they are attached to form a five- to seven-membered heterocyclic ring, which may be saturated or unsaturated and comprises from 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and is optionally substituted from 1 to 4 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, hydroxyl, cyano, oxo, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
- and
- v is 1 to 8.
17 more elements
Dependencies are inferred from the claim text.